LYEL LYELL IMMUNOPHARMA INC

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET.

A live webcast of the presentation can be accessed through the Investors section of the Company's website at Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date.

About Lyell Immunopharma, Inc.

Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit

Contact:

Ellen Rose

Senior Vice President, Communications and Investor Relations



EN
04/06/2025

Underlying

LYELLYELL IMMUNOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LYELL IMMUNOPHARMA INC

 PRESS RELEASE
Free
LYEL LYELL IMMUNOPHA...

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Se...

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data recently in an oral session at the International Conference on M...

June 23, 2025 1 EN
 PRESS RELEASE
Free
LYEL LYELL IMMUNOPHA...

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating ...

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ ...

June 17, 2025 1 EN
 PRESS RELEASE
Free
LYEL LYELL IMMUNOPHA...

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities wi...

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cance...

June 9, 2025 1 EN
 PRESS RELEASE
Free
LYEL LYELL IMMUNOPHA...

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthca...

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's websit...

June 4, 2025 1 EN
 PRESS RELEASE
Free
LYEL LYELL IMMUNOPHA...

Lyell Immunopharma Reports Business Highlights and Financial Results f...

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in ...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch